pt en


Lymphact is a biopharmaceutical start-up focused on developing innovative personalized medical treatments.

Our products and technologies are designed to harness the power of the immune system, the target-specific cellular mechanism which evolved in vertebrates during the last 450 million years, towards a permanent elimination of pathogens. After 5 years of pioneering research and development in this field, we created a new technology platform which can generate autologous and heterologous cellular immune therapies for clinical applications – the DOT-Cells®.

DOT-Cells® can target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs, believed to cause disease recurrence. An improved anti-tumour function and the absence of severe associated side-effects are distinctive and unique features of our therapeutic approach.

Chairmand and CEO
Diogo R. Anjos

This site uses cookies. Some of the cookies we use are essential for parts of the site to operate and have already been set.
You may delete and block all cookies from this site, but parts of the site will not work.